Home/Pipeline/MO-728

MO-728

Ulcerative Colitis

Phase 2Active

Key Facts

Indication
Ulcerative Colitis
Phase
Phase 2
Status
Active
Company

About Mochida Pharmaceutical

Mochida Pharmaceutical is a mission-driven company focused on contributing to human health through the creation of innovative pharmaceuticals. It has achieved a dominant position in the Japanese market with a diversified portfolio and a robust, fully integrated operational model. Its core strategy balances the steady cash flows from its consumer healthcare and diagnostic businesses with targeted R&D investments in novel prescription drugs, supplemented by strategic global partnerships to access new technologies and markets. With a market capitalization of $127.8 billion, it represents a cornerstone of stability and long-term value in the biopharmaceutical sector.

View full company profile

Other Ulcerative Colitis Drugs

DrugCompanyPhase
PALI-2108Palisade BioPhase 2
ALTB-268AltruBioPhase IIa
AIM-HI-UCPathAIClinical Trials
Patient Stratification in Ulcerative ColitisEnable MedicineResearch
Mesalazine (Lifecycle Management)Dr. Falk PharmaApproved/Phase 3
AhR Agonist ProgramAzora TherapeuticsPhase 1b
R-3750VirticiPhase 1
GPR35 InhibitorThirtyFiveBioPreclinical
BEN-8744BenevolentAIPhase 1b
BT-600Biora TherapeuticsPhase 1
Asacol® (mesalazine)Tillotts PharmaApproved
MB310MicrobioticaPhase 1b